The new IVD Regulation 2017/746: a case study at a large university hospital laboratory in Belgium demonstrates the need for clarification on the degrees of freedom laboratories have to use lab-developed tests to improve patient care
-
Pieter. Vermeersch
,
Tobias Van Aelst
Abstract
Objectives
The new European In Vitro Diagnostic (IVD) Regulation 2017/746 (IVDR) restricts the use of lab-developed tests (LDT) after 26th May 2022. There are no data on the impact of the IVDR on laboratories in the European Union.
Methods
Laboratory tests performed in UZ Leuven were divided in four groups: core laboratory, immunology, special chemistry, and molecular microbiology testing. Each test was classified as Conformité Européenne (CE)-IVD, modified/off-label CE-IVD, commercial Research Use Only (RUO) or LDT. Each matrix was considered a separate test.
Results
We found that 97.6% of the more than 11.5 million results/year were generated with a CE-IVD method. Of the 922 different laboratory tests, however, only 41.8% were CE-IVD, 10.8% modified/off-label CE-IVD, 0.3% RUO, and 47.1% LDT. Off-label CE-IVD was mainly used to test alternative matrices not covered by the claim of the manufacturer (e.g., pleural or peritoneal fluid). LDTs were mainly used for special chemistry, flow cytometry, and molecular testing. Excluding flow cytometry, the main reasons for the use of 377 LDTs were lack of a CE-IVD method (71.9%), analytical requirements (14.3%), and the fact the LDT was in use before CE-IVD available (11.9%).
Conclusions
While the large majority of results (97.6%) were generated with a CE-IVD method, only 41.8% of laboratory tests were CE-IVD. There is currently no alternative on the market for 71.5% of the 537 LDTs performed in our laboratory which do not fall within the scope of the current IVD directive (IVDD). Compliance with the IVDR will require a major investment of time and effort.
Acknowledgments
We thank Dirk Stynen for critically reviewing the manuscript and hosting Tobias his internship. We also thank the biomedical science students who helped collect the data during their internship. PV is a senior clinical investigator of the FWO-Vlaanderen.
Research funding: None declared.
Author contributions: All authors have accepted responsibility for the entire content of this manuscript and approved its submission.
Competing interests: Authors state no conflict of interest.
Ethical approval: The local Institutional Review Board deemed the study exempt from review.
References
1. Regulation (EU). 2017/746 of the European Parliament and of the Council of 5 April 2017 on in vitro diagnostic medical devices and repealing directive 98/79/EC and Commission Decision 2010/227/EU. Available from: https://eur-lex.europa.eu/eli/reg/2017/746/oj.Search in Google Scholar
2. Moan, B, Rabin, N. In vitro medical devices: how businesses can successfully comply with the new European regulation. Ann Biol Clin 2018;76:716–18. https://doi.org/10.1684/abc.2018.1369.Search in Google Scholar PubMed
3. van Drongelen, A, de Bruijn, A, Pennings, J, van der Maaden, T. The impact of the new European IVD classification rules on the notified body involvement. A study on the IVDs registered in the Netherlands. RIVM Letter report 2018-0082.Search in Google Scholar
4. Seger, C, Salzmann, L. After another decade: LC-MS/MS became routine in clinical diagnostics. Clin Biochem 2020 Mar 15, https://doi.org/10.1016/j.clinbiochem.2020.03.004 [Epub ahead of print].Search in Google Scholar PubMed
5. Corman, V, Landt, O, Kaiser, M, Molenkamp, R, Meijer, A, Chu, DKW, et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Euro Surveill 2020;25:2000045. https://doi.org/10.2807/1560-7917.ES.2020.25.3.2000045.Search in Google Scholar PubMed PubMed Central
6. De Bruijn, ACP, Roszek, BR. In-huis ontwikkelde IVD testen: gebruik en kwaliteitsborging. Rijksinstituut voor Volksgezondheid en Milieu. RIVM Briefrapport 2015-0152.Search in Google Scholar
7. Diaceutics. What does the EU IVD Regulation mean for companion diagnostics and LDTs?. Available from: https://www.diaceutics.com/?expert-insight=eu-ivd-regulation-mean-companion-diagnostics-ldts [Accessed 26 May 2020].Search in Google Scholar
© 2020 Walter de Gruyter GmbH, Berlin/Boston
Articles in the same Issue
- 10.1515/cclm-2020-frontmatter1
- Mario Plebani turns 70
- Editorial
- Measurement uncertainty and the importance of correlation
- Reviews
- Untangling the association between prostate-specific antigen and diabetes: a systematic review and meta-analysis
- The emerging role of cell senescence in atherosclerosis
- Mini Review
- Minimum retesting intervals in practice: 10 years experience
- Opinion Paper
- Cardiotoxic effects and myocardial injury: the search for a more precise definition of drug cardiotoxicity
- EFLM Papers
- The CRESS checklist for reporting stability studies: on behalf of the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) Working Group for the Preanalytical Phase (WG-PRE)
- Thoughts and expectations of young professionals about the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)
- Guidelines and Recommendations
- Evidence on clinical relevance of cardiovascular risk evaluation in the general population using cardio-specific biomarkers
- Genetics and Molecular Diagnostics
- A systematic evaluation of stool DNA preparation protocols for colorectal cancer screening via analysis of DNA methylation biomarkers
- General Clinical Chemistry and Laboratory Medicine
- The new IVD Regulation 2017/746: a case study at a large university hospital laboratory in Belgium demonstrates the need for clarification on the degrees of freedom laboratories have to use lab-developed tests to improve patient care
- Evaluation of serum electrolytes measurement through the 6-year trueness verification program in China
- Feasibility for aggregation of commutable external quality assessment results to evaluate metrological traceability and agreement among results
- Sample size and rejection limits for detecting reagent lot variability: analysis of the applicability of the Clinical and Laboratory Standards Institute (CLSI) EP26-A protocol to real-world clinical chemistry data
- Effects of calcium dobesilate (CaD) interference on serum creatinine measurements: a national External Quality Assessment (EQA)-based educational survey of drug-laboratory test interactions
- Mass spectrometric sample identification with indicator compounds introduced via labeled sample tubes
- Automation and validation of a MALDI-TOF MS (Mass-Fix) replacement of immunofixation electrophoresis in the clinical lab
- A new strategy implementing mass spectrometry in the diagnosis of congenital disorders of N-glycosylation (CDG)
- Analytical evaluation of four faecal immunochemistry tests for haemoglobin
- Reference Values and Biological Variations
- Study of total error specifications of lymphocyte subsets enumeration using China National EQAS data and Biological Variation Data Critical Appraisal Checklist (BIVAC)-compliant publications
- Mass spectrometric quantification of urinary 6-sulfatoxymelatonin: age-dependent excretion and biological variation
- Establishment of international autoantibody reference standards for the detection of autoantibodies directed against PML bodies, GW bodies, and NuMA protein
- Hematology and Coagulation
- Appropriate thresholds for accurate screening for β-thalassemias in the newborn period: results from a French center for newborn screening
- Cardiovascular Diseases
- Analysis of B-type natriuretic peptide impurities using label-free data-independent acquisition mass spectrometry technology
- Diabetes
- Hemoglobin variants in southern China: results obtained during the measurement of glycated hemoglobin in a large population
- Potential of MALDI-TOF mass spectrometry to overcome the interference of hemoglobin variants on HbA1c measurement
- Acknowledgment
- Acknowledgment
- Letter to the Editors
- Measurement uncertainty estimation for derived biological quantities
- Non-reproducible cardiac troponin results occurring with a particular reagent lot
- Successfully meeting analytical expectations for the fast 0/1-h algorithm for NSTEMI by internal control procedures for cardiac troponin T
- Performance of perpendicular drop versus tangent skimming gating of M-protein in proficiency testing challenges
- Analytical evaluation of Reebio procalcitonin latex-enhanced immunoturbidimetric assay on the HITACHI Labospect 008AS
- Assessment of intraindividual agreement in prolactin results after post-polyethylene glycol precipitation test for the estimation of macroprolactin. Should the precipitation procedure be repeated in the same patient?
- Aggregation kinetic and temperature optimum of an EDTA-dependent pseudothrombocytopenia
Articles in the same Issue
- 10.1515/cclm-2020-frontmatter1
- Mario Plebani turns 70
- Editorial
- Measurement uncertainty and the importance of correlation
- Reviews
- Untangling the association between prostate-specific antigen and diabetes: a systematic review and meta-analysis
- The emerging role of cell senescence in atherosclerosis
- Mini Review
- Minimum retesting intervals in practice: 10 years experience
- Opinion Paper
- Cardiotoxic effects and myocardial injury: the search for a more precise definition of drug cardiotoxicity
- EFLM Papers
- The CRESS checklist for reporting stability studies: on behalf of the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) Working Group for the Preanalytical Phase (WG-PRE)
- Thoughts and expectations of young professionals about the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)
- Guidelines and Recommendations
- Evidence on clinical relevance of cardiovascular risk evaluation in the general population using cardio-specific biomarkers
- Genetics and Molecular Diagnostics
- A systematic evaluation of stool DNA preparation protocols for colorectal cancer screening via analysis of DNA methylation biomarkers
- General Clinical Chemistry and Laboratory Medicine
- The new IVD Regulation 2017/746: a case study at a large university hospital laboratory in Belgium demonstrates the need for clarification on the degrees of freedom laboratories have to use lab-developed tests to improve patient care
- Evaluation of serum electrolytes measurement through the 6-year trueness verification program in China
- Feasibility for aggregation of commutable external quality assessment results to evaluate metrological traceability and agreement among results
- Sample size and rejection limits for detecting reagent lot variability: analysis of the applicability of the Clinical and Laboratory Standards Institute (CLSI) EP26-A protocol to real-world clinical chemistry data
- Effects of calcium dobesilate (CaD) interference on serum creatinine measurements: a national External Quality Assessment (EQA)-based educational survey of drug-laboratory test interactions
- Mass spectrometric sample identification with indicator compounds introduced via labeled sample tubes
- Automation and validation of a MALDI-TOF MS (Mass-Fix) replacement of immunofixation electrophoresis in the clinical lab
- A new strategy implementing mass spectrometry in the diagnosis of congenital disorders of N-glycosylation (CDG)
- Analytical evaluation of four faecal immunochemistry tests for haemoglobin
- Reference Values and Biological Variations
- Study of total error specifications of lymphocyte subsets enumeration using China National EQAS data and Biological Variation Data Critical Appraisal Checklist (BIVAC)-compliant publications
- Mass spectrometric quantification of urinary 6-sulfatoxymelatonin: age-dependent excretion and biological variation
- Establishment of international autoantibody reference standards for the detection of autoantibodies directed against PML bodies, GW bodies, and NuMA protein
- Hematology and Coagulation
- Appropriate thresholds for accurate screening for β-thalassemias in the newborn period: results from a French center for newborn screening
- Cardiovascular Diseases
- Analysis of B-type natriuretic peptide impurities using label-free data-independent acquisition mass spectrometry technology
- Diabetes
- Hemoglobin variants in southern China: results obtained during the measurement of glycated hemoglobin in a large population
- Potential of MALDI-TOF mass spectrometry to overcome the interference of hemoglobin variants on HbA1c measurement
- Acknowledgment
- Acknowledgment
- Letter to the Editors
- Measurement uncertainty estimation for derived biological quantities
- Non-reproducible cardiac troponin results occurring with a particular reagent lot
- Successfully meeting analytical expectations for the fast 0/1-h algorithm for NSTEMI by internal control procedures for cardiac troponin T
- Performance of perpendicular drop versus tangent skimming gating of M-protein in proficiency testing challenges
- Analytical evaluation of Reebio procalcitonin latex-enhanced immunoturbidimetric assay on the HITACHI Labospect 008AS
- Assessment of intraindividual agreement in prolactin results after post-polyethylene glycol precipitation test for the estimation of macroprolactin. Should the precipitation procedure be repeated in the same patient?
- Aggregation kinetic and temperature optimum of an EDTA-dependent pseudothrombocytopenia
